Investor Presentation

117 Investor presentation First six months of 2022 Region China at a glance. Region China Million Diabetes trend Diabetes market by value and Novo Nordisk market share Novo Nordisk reported sales DKK billion 200 30 6% 14% 160 25 74.3%1 First half of 2022 Sales (mDKK) Growth² 100% Total GLP-13 1,672 83% 80% Long-acting insulin4 959 -13% 20 120 20 Premix insulin5 2,602 -11% 60% Fast-acting insulin6 1,097 -14% Insulin 15 Human insulin 175 1,011 -32% 80 164 13.9%1 40% 141 10 10 Total insulin 5,669 -17% 40 40 Other Diabetes care? 691 -25% 20% 5 8.5%1 OAD Diabetes care 8,032 -7% 0 2021 0 0% Obesity care (SaxendaⓇ) 78 350% May 2030 2045 2017 May 2022 Diabetes & Obesity care 8,110 -6% Population with diabetes Diabetes growth rate -GLP-1 MS -Insulin MS -OAD MS Rare disease8 297 58% Total 8,407 -5% Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021 Region China covers Mainland China, Taiwan, and Hong Kong 1 CAGR calculated for last 5-year period Competitor insulin value market shares, as of May 2022: Novo Nordisk 50%, Sanofi 17%, Gan & Lee 13% and Eli Lilly 8%; Competitor GLP-1 value market shares, as of May 2022: Novo Nordisk 67% and Eli Lilly 25% OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, May 2022 value figures 2 At constant exchange rates; 3 Comprises Victoza® and OzempicⓇ; 4 Comprises Tresiba®, XultophyⓇ and LevemirⓇ: 5 Comprises NovoMixⓇ and RyzodegⓇ; 6 Comprises NovoRapidⓇ; 7 Comprises Novo NormⓇ and needles; 8 Comprises primarily NovoSeven®, NovoEight® and Norditropin® Source: Quarterly company announcement

View entire presentation